AstraZeneca Investor Day Presentation Deck
Conclusions
20
Olaparib + abiraterone led to a significant and clinically meaningful improvement
in rPFS (HR 0.66 [95% CI 0.54-0.81]) over placebo + abiraterone in 1L mCRPC
Benefit observed led to a median rPFS beyond 2 years
Benefit was observed irrespective of HRRm status
Secondary and exploratory endpoints support the treatment benefit of
olaparib + abiraterone over placebo + abiraterone in the overall patient population
The safety profile of olaparib + abiraterone was consistent with the safety profile for the individual
drugs and there was no detriment to quality of life allowing most patients to stay on therapy
The Phase III PROpel study is the first combination approach to deliver consistent
clinical benefits for patients in the 1L mCRPC setting, irrespective of HRRm status
4View entire presentation